BACKGROUND: Cardiovascular diseases remain the predominant cause of death worldwide, with the prevalence of heart failure continuing to increase. Despite increased knowledge of the metabolic alterations that occur in heart failure, novel therapies to treat the observed metabolic disturbances are still lacking.
H
eart failure (HF) continues to emerge as a devastating disease in terms of morbidity and mortality worldwide. HF is defined as any cardiac dysfunction at imaging with concomitant clinical symptoms of decompensation. The estimated total cost caused by HF in 2012 was $108 billion per year worldwide, and this number is expected to increase incrementally because of a rapidly expanding and aging population. 1 Arterial hypertension in particular remains 1 of the serious burdens implicated in heart failure progression. 2 Structural cardiac changes in HF are accompanied by undesirable metabolic alterations. Dysfunctional cardiomyocytes switch from fatty acid oxidation to increased glucose metabolism, with a general decrease in oxidative metabolism. [3] [4] [5] The fetal switch, named because of similarities with the metabolism of a fetal heart, is a hallmark event in the dismal evolution of heart failure.
MicroRNAs were discovered ≈15 years ago, and consensus indicates that these small noncoding RNAs, important posttranscriptional modifiers of their target genes, influence many cellular processes simultaneously. 6, 7 In the last 2 decades, multiple microRNAs (eg, microRNA-155, microRNA-25, and microRNA-199, among others) have been implicated in the process of cardiac hypertrophy on pressure overload. [8] [9] [10] MicroRNA-146a has been implicated in inflammation, angiogenesis, and tumor formation. 11, 12 Reports indicate increased expression of microRNA-146a during peripartum 13 or toxic cardiomyopathies, 14 but conclusive evidence for its involvement in the progression of cardiac hypertrophy to cardiac dysfunction or HF on pressure overload is lacking. In our study, we describe a novel role for microRNA146a in the development of cardiac hypertrophy and left ventricular (LV) dysfunction on pressure overload. We show that microRNA-146a suppresses oxidative cardiomyocyte metabolism. MicroRNA-146a targets dihydrolipoyl succinyltransferase (DLST), a key component of the α-ketoglutarate dehydrogenase complex. Furthermore, overexpression of DLST in cardiomyocytes protects the heart from cardiac dysfunction on pressure overload in vivo, suggesting that metabolic elementsand their microRNA regulators-form attractive therapeutic targets for LV dysfunction.
METHODS

Human Heart Samples: Ethics
Approval for studies on human tissue samples was obtained from the Medical Ethics Committee of the Maastricht University Hospital, The Netherlands; or from the Medical Ethics Committee of Leuven University Hospital, Belgium. All patients or their relatives gave written informed consent before operation. All applicable protocols involving the collection or use of patient materials respected the Declaration of Helsinki.
Description of Animals
MicroRNA-146a
-/-mice were kindly provided by Dr David Baltimore and were produced as described elsewhere. 15 These mice are in C57BL6/NTAC background. MicroRNA-146a CMC-TG mice were kindly provided by Dr Yigal Pinto. These cardiomyocyte-specific microRNA-146a overexpressing animals were created by transgenesis using a vector containing the full-length mature mmu-microRNA-146a sequence driven by an α-myosin heavy chain promoter. These mice are in C57BL6/J x FVB mixed background.
For the studies exclusively performed in wild-type animals, 2 commercial sources (Janvier and Charles River) were used. For the studies in genetically manipulated mice (the microRNA146a -/-colony and the microRNA-146a CMC-TG colony), the bred wild-type littermates were always used as controls.
Animal Procedures
All animal studies were performed in accordance with local institutional guidelines and regulations, including approval for all animal experiments by the local Ethical Committee for Animal Experiments of KU Leuven, Belgium. All applicable protocols respected the Declaration of Helsinki. Furthermore, although no a priori power analysis was performed, a limited number of animals was used to respect animal welfare regulations. Experimental numbers were based on previous experience with the used animal models. No specific randomization techniques were used.
Angiotensin-II (Ang-II) Administration
Recombinant human Ang-II (sequence: N-Asp-Arg-Val-TyrIle-His-Pro-Phe-COOH) was commercially purchased (H-1705,
Clinical Perspective
What Is New?
• Mechanistically, we observed that microRNA-146a contributes to decreased dihydrolipoyl succinyltransferase levels, impairing energy metabolism in the pressure-overloaded heart.
What Are the Clinical Implications?
• From a clinical point of view, these data open a new area of research on the influence of microRNAs in metabolic remodeling in heart failure, as well as shed light on novel therapies that try to reverse or amend metabolic disturbances in heart failure.
• A therapeutic approach that improves the energy efficiency of the failing heart is complementary to existing heart failure therapies that basically unload the heart but only have limited effects on myocardial energy metabolism.
• Furthermore, from a mechanistic point of view, improving myocardial energetics could be beneficial for all forms of heart failure (heart failure with reduced ejection fraction, heart failure with minimally reduced ejection fraction, and heart failure with preserved ejection fraction).
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Bachem AG) as a lyophilized powder and was subsequently solubilized in NaCl 0.9% according to the manufacturer's guidelines. The solute was administered in an osmotic pump (Alzet 2004, Durect Corp.) taking into account the preparative instructions of the manufacturer. After priming for 24 hours at 37°C, pumps were subcutaneously implanted on the dorsal side of the mice in a craniocaudal orientation. The 8-week-old mice were gas anaesthetized with isoflurane induction for 1 minute with isoflurane 4% in oxygen, mean 1.5% in oxygen during the procedure. The implantation was done in a sterile manner; mice were sutured with Vicryl Plus 5-0 (Ethicon, Johnson & Johnson Medical). Ang-II was administered at a dose of 2.5 mg/kg/d for 28 days.
Transversal Aortic Banding
For transversal aortic banding, 11-week-old mice were anaesthetized with Nembutal (pentobarbital) (9 mg/mL; 0.05 mL/g bodyweight intraperitoneally). After intubation and mechanical ventilation, the chest was opened in a sterile manner. The aortic arch was ligated with Vicryl Plus 5-0 suture; a 90% ligation was established using a 27-gauge needle. After the procedure, mice were closely monitored for 24 hours on stable temperature (37°C) until full recovery. Body temperature was maintained at 37°C using an infrared lamp regulated by a feedback system connected to a T-thermocouple rectal probe.
Transthoracic Echocardiography
Before transthoracic echocardiography, the chests of the mice were shaved and treated with a hair-removing cream (Veet, Reckitt Benckiser); mice were lightly anaesthetized with isoflurane (induction with 4% and during the procedure mean 1.5% in oxygen) and allowed to breathe spontaneously through a nasal cone. Noninvasive echocardiographic parameters were measured using a digital cardiac ultrasound platform (Vevo 2100 and 7000, Visualsonics Inc.) with an 18-MHz linear scanner (MicroScan, Visualsonics Inc.).
Anti-miR Administration
Anti-miR-146a for in vivo applications was synthetized by RiboTask ApS and Exiqon A/S. The anti-miR was a full-length oligonucleotide directed against the mature sequence of mmu-microRNA-146a and was modified with locked nucleic acid technology to ensure stability. The scrambled control sequence contained the same amount of building blocks (ACGT) but in a random order. Anti-miR or scrambled control was administered at days +1 and +4. The dose applied per injection was 5 mg/kg total body weight. Anti-miRs were solubilized in NaCl 0.9%.
rAAV9 Vector Production and Administration
The production and quality control of the rAAV9 vectors used in this study was performed as described elsewhere. 16 Briefly, the coding sequence of the murine DLST gene (RefSeq NM_030225.4) was synthetized, commercially purchased, and subsequently cloned into a pAAV-TF-CMV-intron-GFP-MCS vector with restriction (AgeI-SpeI) and ligation technology. Cloning steps were regularly verified by DNA sequencing.
Before large-scale production of rAAV9-DLST vectors, overexpression of DLST protein was verified by Western blotting. The control vector contained an insert gene coding for Firefly luciferase, which allowed us to control the presence of rAAV9 particles in the heart in vivo by means of bioluminescence imaging by administering luciferin intraperitoneally (D-luciferin, Sigma Aldrich). The rAAV9-DLST pool was spiked with 5% of control vector, allowing us to have an indication of rAAV9-DLST delivery in the heart as well. Viral titers for the produced vectors were as follows: 3.72 x 10 11 GC/mL for the rAAV9-DLST vector and 9.46 x 10 11 GC/mL for the rAAV9-control vector. Vector stocks were diluted as to inject 1.86 x 10 10 particles per mouse with a reference body weight of 25 grams.
In Vitro Assays
Cell Cultures
Neonatal rat cardiomyocytes were isolated as extensively described elsewhere. Briefly, neonatal rat ventricular cardiac myocytes were isolated by enzymatic dissociation of 1-to 2-day-old hearts of Lewis rat pups plated on gelatinized 6-well plates and cultured as previously described.
17,18
Luciferase Assays
Luciferase assays were performed on a GloMax-96 luminometer (Promega). The pEZX-MT01 vector (Genecopoeia) was commercially purchased and contained the full-length 3'-UTR of mmu-DLST. The site-directed mutagenesis was performed using the Agilent-Stratagene Quikchange-II XL kit. Confirmation of the mutations was done with conventional Sanger-based sequencing.
Metabolic Flux Experiments
Adult mouse cardiac cells were extracted by enzymatic digestion (collagenase I). The hearts were dissected and immediately perfused with calcium-free Tyrode solution by a Langendorff perfusion system. After enzymatic digestion, calcium was slowly reintroduced. Cells could be kept in culture for 24 hours in BDM-enriched medium. Freshly isolated adult cardiomyocytes were plated on laminin-coated cell culture plates. Metabolic fluxes were measured using radiolabeled tracer glucose and palmitate (all tracers were from American Radiolabeled Chemicals). Glycolysis was measured as H 2 O. The vials were incubated for 48 hours at 37°C. Afterward the filter papers were transferred to scintillation vials containing 5 mL of scintillation fluid (Lumasafe 3087, Perkin Elmer) and counted with the Tri-Carb 2900TR Liquid Scintillation Analyzer (Perkin Elmer). Glucose oxidation was assessed as 14 CO 2 formation using [6] [7] [8] [9] [10] [11] [12] [13] [14] C]-D-glucose as a tracer. Cardiomyocytes were incubated for 2 hours with medium containing labeled [6] [7] [8] [9] [10] [11] [12] [13] [14] C]-D-glucose. Perchloric acid (HClO 4 ) (250 μL, 3 mol/L) was used to stop cellular metabolism and lyse the cells. The release of intracellular CO 2 was captured by Whatman filter papers soaked in hyamine covering the lid over a period of 24 hours at room temperature. Next, the filter papers were transferred to scintillation vials and counted by the Scintillation Analyzer. Oxygen consumption rate (OCR) was measured using the extracellular flux analyzer XF24 (Seahorse Bioscience Inc.). In baseline conditions, 5 consecutive measurements of OCR were performed. Next, oligomycin, a blocker of ATP synthase, was injected at a final concentration of 1.2 μM. The drop in OCR reflected the oxygen consumption serving ATP production. OCR ATP was calculated as the difference between OCR before and after oligomycin administration. The proton leak was calculated as the difference between the baseline OCR and the OCR ATP. In parallel wells, dinitrophenol, a mitochondrial uncoupler, was injected at a final concentration of 0.1 mM. This forced cardiomyocytes to use their maximal mitochondrial capacity to preserve the mitochondrial membrane potential. The increase in OCR reflected the reserve capacity of mitochondria. As a second injection, anti-mycin-A was added at a final concentration of 1 μM, a complex III inhibitor. This shut down the electron transport chain activity, abolishing the mitochondrial oxygen consumption. The residual OCR corresponded to the nonmitochondrial oxygen consumption. All mitochondrial inhibitors were from Sigma Aldrich.
HISTOLOGY Preparation of Samples
For histological analysis, hearts were arrested in diastole by means of KCl buffer. All organs were fixed with 1% paraformaldehyde for 24 hours, postfixed in ethanol 70% for 24 hours, and subsequently embedded in paraffin and cut into 4-to 5-μm sections.
Conventional Chemical Stainings
Paraffin sections were stained with hematoxylin and eosin for routine histological analysis and Sirius Red for detection of fibrillar collagen. Slides were visualized using a Zeiss Axioplan 2 Imager microscope (CarlZeiss Inc.) with an AxioCamHR camera (CarlZeiss Inc.).
Immunohistochemistry
For immunohistochemical analysis, hearts were arrested in diastole, perfusion fixed with 4% paraformaldehyde, embedded in paraffin, and cut into 4-μm sections. The following antibodies were used: anti-CD31-antibody (557355, Pharmingen), anti-CD45-antibody (553076, Pharmingen), and anti-laminin antibody (L9393, SigmaAldrich). Secondary antibodies (P0449/P0260/0450, Dako) were labeled with horseradish peroxidase. Visualization was performed with diaminobenzidine (002114, Invitrogen Life Technologies) staining. Quantifications of positively stained cells and cell surface areas were determined using KS400 software (CarlZeiss Inc.).
In Situ Hybridization
For in situ hybridization, hearts were arrested in diastole, fixed with 4% paraformaldehyde, embedded in paraffin, and cut into 4-μm sections. Paraffin sections were stained with a miRCURY locked nucleic acid micro-RNA 146a detection probe (Exiqon A/S). The product sequence is 5'-AACCCATGGAATTCAGTTCTCA-3' and the probe is double-DIG (digoxigenin) labeled. Visualization was performed with an alkaline phosphatase-linked anti-DIG antibody (11093274910, RocheApplied-Science), after which nitro blue tetrazolium chloride and 5-bromo-4-chloro-3-indolyl phosphate were administered (NBT-BCIP tablets, 11697471001, Roche-Applied-Science). Slides were visualized using a Zeiss Axioplan 2 Imager microscope with an AxioCam-HR camera.
Western Blotting
The extraction of proteins from tissue material, preparation of samples, SDS polyacryl amide gel electrophoresis, Western blotting, and development of the blots were extensively described elsewhere. 8 Antibodies used for Western blotting were anti-mouse monoclonal DLST produced in rabbit (ab177934, Abcam) and anti-mouse monoclonal GAPDH produced in mice (10R-G109b, Fitzgerald). For detection of proteins, the Pierce ECL substrate kit (32106, Thermo Scientific) was used on a BioRad Imager facility (Chemidoc XRS, BioRad).
Real-Time Quantitative Polymerase Chain Reaction
All locked nucleic acid -based microRNA primers were designed by Exiqon A/S. All other primers were designed by Eurogentec or Integrated DNA Technology. RNA from LV mouse heart tissue was extracted with the Ambion miRVANA RNA extraction kit (AM1560, Applied Biosciences) according to the manufacturer's instructions; 500 to 1000 nanograms of RNA were subsequently reverse-transcribed to cDNA using the miScript-II real-time polymerase chain reaction kit (218061, Qiagen Benelux NV). Real-time polymerase chain reaction was performed on an ABI-Prism cycler (Applied Biosystems, Life Technologies) using SYBR Green (Life Technologies). Transcript quantities were compared using the relative Ct method, where the amount of target normalized to the amount of endogenous control (GAPDH or U6) and relative to the control sample is given by 2-∆∆Ct. Figure 1 . MicroRNA-146a is expressed in cardiac tissue and upregulated on pressure overload. A, Schematic representation of the different experimental models used. B, MicroRNA-146a is significantly upregulated in whole heart tissue after 4 weeks of continuous angiotensin-II administration (n=4-5). C, MicroRNA-146a is significantly upregulated in whole heart tissue 3 weeks after transversal aortic banding (n=7). D, MicroRNA-146a is significantly upregulated after 4 weeks of continuous infusion of angiotensin-II in combination with isoproterenol (n=5-6). E, Schematic and simplified representation of the relation among arterial hypertension, aortic stenosis, and left ventricular hypertrophy. F and G, The array signal and validation quantitative polymerase chain reaction of microRNA-146a show that it is significantly upregulated in patients with aortic stenosis and left ventricular hypertrophy. H, MicroRNA-146a levels in whole heart tissue correlate with left ventricular average wall thickness. I, In situ hybridization showing staining of microRNA146a in cardiac myocytes (arrowheads). The dashed line delineates a capillary structure (scale bar represents 15 µm). J, In situ hybridization of whole heart tissue shows expression of microRNA-146a in endothelial cells and cardiac myocytes (scale bar = 50 µm) (Left), Haematoxylin & eosin control (scale bar = 50 µm) (Right). Ang-II indicates angiotensin-II; AoS, aortic stenosis; ISH, in situ hybridization; ISO, isoproterenol; and TAC, transversal aortic constriction. All data shown are as mean+SEM.*P<0.05; **P<0.01.
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Target Prediction
Putative microRNA target genes were identified using the microRNA databases and target prediction tools miRBase (http://microrna.sanger.ac.uk/) and TargetScan (http://targetscan.org/index.html). The miRWalk database and www.microrna.org were also consulted.
Statistics
Data represent mean±SEM of representative experiments unless otherwise stated. For all in vitro experiments, every experiment was performed ≥2 times. Statistical outliers were not automatically excluded; only technical failures were excluded from the datasets. Data analysis was performed by an investigator unaware of the group allocation. Normality testing was performed with the Kolmogorov-Smirnov and Shapiro-Wilk normality test (Prism v5.0d). Statistical significance for multiple group comparisons was calculated by 2-way analysis of variance with Bonferroni post hoc testing. For comparison between 2 groups, a standard Student's t test was used for normally distributed data, and a Mann-Whitney test was used for non-normally distributed data. For correlation analysis, a Spearman correlation coefficient was calculated. A 2-sided P value of <0.05 was considered statistically significant.
RESULTS
MicroRNA-146a Is Upregulated in Cardiac Tissue During Pressure Overload
When mice were subjected to pressure overload, by pharmacological stimulation (Ang-II alone or combined with isoproterenol) or through transversal aortic constriction, a significant increase in microRNA-146a levels was observed in the left ventricle (Figure 1a through  1d) . These pressure overload models partially mimic the events happening in the human setting of aortic stenosis or arterial hypertension, leading to LV hypertrophy and dysfunction (Figure 1e) . Similarly, microRNA-146a levels moderately increased in a microarray of patients with aortic stenosis versus controls (Figure 1f , Table I in the online-only Data Supplement), subsequently validated by quantitative polymerase chain reaction (Figure 1g) . Cardiac microRNA-146a levels correlated with echocardiographic average LV wall thickness in diastole (Figure 1h) . In situ hybridization of microRNA-146a revealed a clear signal in the cardiomyocytes as well as in the endothelial cells delineating the capillaries (Figure 1i and 1j). To explore further the possible cell-cell communication between these 2 cell types, cardiac endothelial cells were transfected with microRNA-146a mimics and isolated exosomes were subsequently placed on the cultured cardiomyocytes. Endothelial-derived exosomes resulted in increased levels of atrial natriuretic factor and brain natriuretic peptide ( Figure Id through If in the online-only Data Supplement) and could be visualized within the cardiomyocytes ( Figure I in the online-only Data Supplement). Thus, microRNA-146a is expressed in the heart by cardiomyocytes and endothelial cells and upregulated on pressure overload in mice and humans.
Manipulation of MicroRNA-146a Levels in Mice Affects the Cardiac Response to Pressure Overload
Viable global microRNA-146a knockout mice (hereafter called microRNA-146a-/ -mice) and their wild-type littermates were subjected to Ang-II for 4 weeks via an osmotic minipump (Figure 2a ). Heart weight significantly increased after 4 weeks of Ang-II in wild-type mice, whereas microRNA-146a-/ -mice had a blunted hypertrophic response (Figure 2b and 2c) . Furthermore, the increase in cardiomyocyte cell surface area was significantly lower in microRNA-146a-/ -than wild-type mice (Figure 2f) , with no significant effect of microR-NA-146a absence on collagen deposition, leukocyte infiltration, and capillary density (Figure 2d , Table II in the online-only Data Supplement). Moreover, fractional shortening-a marker of cardiac systolic functiondecreased in wild-type mice on Ang-II, whereas it was preserved in microRNA-146a-/ -mice ( Figure 2e , Table  III in the online-only Data Supplement).
Treatment of wild-type mice with specific oligonucleotides against microRNA-146a (anti-miR-146a) (Figure 2a , Figure II in the online-only Data Supplement) also resulted in a blunted hypertrophic response (Figure 2g , Figure II in the online-only Data Supplement), confirming the protective effect of microRNA-146a deletion. In line, α-skeletal actin levels, atrial natriuretic factor levels, and cardiomyocyte cell surface area were significantly lower in anti-miR-treated mice versus scrambled controls on Ang-II treatment (Figure 2h and 2k) . Accordingly, anti-miR-146a treatment resulted in preserved cardiac function (fractional shortening, Figure 2j , Table IV in the online-only Data Supplement). MicroRNA-146a inhibition did not affect collagen content, inflammatory cell infiltration, or capillary density in the heart (Figure 2i , Table II in the online-only Data Supplement).
Last, pressure overload was induced in transgenic mice with a cardiomyocyte-restricted microRNA-146a overexpression (hereafter called microRNA-146a CMC-TG mice already had increased heart weights compared with their wild-type littermates, which was further aggravated with Ang-II treatment ORIGINAL RESEARCH ARTICLE Figure 2 . Manipulation of microRNA-146a levels in mice affects the cardiac response to pressure overload. A, Schematic representation of the experimental groups and the timeline of the experiments performed. B and C, In microRNA-146a knockout mice, normalized heart weight increase is significantly blunted compared with their wild-type littermates after angiotensin-II administration, and α-skeletal actin and ANF levels trended toward lower (Continued ) (Figure 2l) . Concomitantly, α-skeletal actin and atrial natriuretic factor levels were strongly increased in the microRNA-146a CMC-TG mice compared with their wild-type littermates (Figure 2m ). The cardiomyocyte cross-sectional area was increased in microR-NA-146a CMC-TG mice compared with their wild-type counterparts, which was even more pronounced after Ang-II infusion (Figure 2p ). Fractional shortening decreased in both wild-type and microRNA-146a overexpressing mice after Ang-II (Figure 2o , Table V in the online-only Data Supplement). Collagen content, inflammatory cell infiltration, and capillary density did not significantly differ between both groups (Figure 2n ). In summary, cardiomyocyte-derived microRNA-146a contributes to the development of cardiac hypertrophy and LV dysfunction, whereas inhibition of microRNA-146a has a protective effect during pressure overload.
We validated our findings in the transversal aortic constriction model ( Figure IIIa in the online-only Data Supplement). A transversal aortic constriction study in the microRNA-146a -/-model was not possible because of the genetic background of the mice provoking ≈85% early mortality in both genotypes (n=20). However, we observed a trend ( Figure IIIc 
MicroRNA-146a Targets DLST
Given the overall lack of effect of microRNA-146a manipulation on inflammation, fibrosis, or angiogenesis, together with the observed effect on cardiac function, we hypothesized that microRNA-146a might target the 3'-UTR of genes involved in cardiomyocyte energy metabolism because the latter is crucially affected in LV dysfunction. The TargetScan algorithm (http://www.targetscan.org) revealed a potential binding of microRNA146a to DLST, the E2 subunit of the α-ketoglutarate dehydrogenase complex, a key rate-controlling step in the tricarboxylic acid cycle (TCA) cycle.
The microRNA-146a sequence, and especially the seed sequence, is highly conserved among mammals (Figure 3a) . It is localized on chromosome 11 in mice and comprises an immature premicroRNA-146a and its products microRNA-146a-5p and microRNA-146a-3p (Figure 3b and 3c) . Analysis of the 3'-untranslated region of DLST mRNA revealed 3 potential binding sites for microRNA-146a (Figure 3d ).
DLST as a microRNA-146a target was further validated using luciferase assays. Three potential binding sites were mutated individually and in combination via site-directed mutagenesis (Figure 3e ). Transfection of a plasmid containing the luciferase sequence followed by the native DLST 3'-untranslated region, together with microRNA-146a mimic, gave rise to a 50% decrease in normalized luciferase activity (Figure 3f ), confirming the microRNA-146a-DLST interaction. Furthermore, single mutations of the DLST binding site only partially affected the binding of the microRNA-146a mimic. Complete inhibition was observed only when binding position 3 was mutated in combination with position 1 and position 2. When we measured DLST protein levels in wild-type animals treated with anti-miR-146a for 4 Figure 2 Continued. values in the knockout mice (n=7-10 per group). D, Overview of representative pictures showing collagen content (Sirius Red), inflammatory cell infiltration (CD45), capillary density (CD31), and cardiomyocyte cross-sectional area (laminin). Scale bar = 100 µm. E and F, Fractional shortening was preserved and cardiomyocyte cross-sectional area increase was blunted in the angiotensin-II treated knockout mice compared with their wild-type littermates. G and H, In anti-miRtreated mice, normalized heart weight increase is significantly blunted compared with the scrambled control-treated counterparts after angiotensin-II administration, and α-skeletal actin and ANF levels were lower in the anti-miR-treated mice (n=5-6 per group). I, Overview of representative pictures showing collagen content (Sirius Red), inflammatory cell infiltration (CD45), capillary density (CD31), and cardiomyocyte cross-sectional area (laminin). Scale bar = 100 µm. J and K, Fractional shortening was preserved and cardiomyocyte cross-sectional area increase was blunted in the angiotensin-II treated anti-miR mice compared with the scrambled controls. L, In microRNA-146a cardiomyocyte-specific overexpressing mice, normalized heart weight increased significantly compared with their wild-type littermates after angiotensin-II administration but also spontaneously on overexpression (n=7-10 per group). M, α-skeletal actin and ANF levels were significantly increased in the angiotensin-II treated transgenic mice. N, Overview of representative pictures showing collagen content (Sirius Red), inflammatory cell infiltration (CD45), capillary density (CD31), and cardiomyocyte cross-sectional area (laminin). Scale bar = 100 µm. O and P, Fractional shortening was equally decreased in both wild-type and transgenic mice on angiotensin treatment, but cardiomyocyte crosssectional area in angiotensin-II-treated mice was strongly increased compared with the wild-type littermates. Quantifications can be found in Table II in the online-only Data Supplement. ANF indicates atrial natriuretic factor; Ang-II, angiotensin-II; ASKA, α-skeletal actin; CMC-TG, cardiomyocyte-specific transgenic animals; EXP, experiment; FS, fractional shortening; HW/TL, heart weight normalized to tibia length; KO, knockout; LV, left ventricle; RV, right ventricle; WT, wild type. All data are shown as mean+SEM. * P<0.05 within genotype but between conditions; #P<0.05 between genotypes within same condition. A, Schematic representation of microRNA-146a sequence preservation, especially of the seed sequence, in mammals. B, Genomic localization and organization of microRNA-146a in mice. C, Full sequence of the mature microRNA-146a and organization of the microRNA-146a-5p and microRNA-146a-3p structures. D, Schematic diagram representing the 3 potential binding sites for microRNA-146a in the 3'UTR of DLST in mice and the corresponding binding sites in humans. E, Schematic diagram representing the site-directed mutagenesis performed in the 3'UTR of murine DLST. Four consecutive nucleotides within the seed sequence were mutated with an ACGG sequence, abolishing potential seed sequence complementarity. F, Luciferase assays finally clearly showed that the 3'UTR of DLST is targeted by microRNA-146a (numbers above bars represent P values). G, DLST protein levels significantly increased after treatment with anti-miR-146a at baseline (quantification of Western blot of whole heart tissue). H and I, DLST protein levels significantly decreased in wild-type mice after 4 weeks of angiotensin-II (H) or 6 weeks of transversal aortic constriction (I) (quantification of Western blots of whole heart tissue). Ang-II indicates angiotensin-II; DLST, dihydrolipoyl succinyltransferase; FLuc, firefly luciferase; mut, mutation; pos, position; RLU, relative luminiscence units; RL, renilla luciferase; and TAC, transversal aortic constriction. All data are shown as mean+SEM. *P<0.05; ** P<0.01; n=6 to 9 per group, 3 independent experiments. A, Schematic representation of the experimental protocol for ex vivo cardiomyocyte extraction. B and C, After 4 weeks of angiotensin-II (Ang-II) treatment in adult mouse cardiomyocytes, fatty acid oxidation was preserved in the angiotensin-II-treated microRNA-146a knockout (KO) mice (B), and glucose oxidation was also preserved in the angiotensin-II-treated microRNA146a mice (C). D, There was no significant difference in glycolytic flux between the 2 genotypes. E, Oxygen consumption rate (OCR) measurements showed no significant differences in basal and maximum OCR between wild-type (WT) and Ang-IItreated cardiomyocytes, whereas OCR to produce ATP was significantly higher in KO cells, and excess proton leak tended to decrease in the KO cells, together pointing to a more energy-efficient use of oxygen in the KO cardiomyocytes. F, Experimental design of the OCR experiments and the role of the different anti-mitochondrial agents. G and J, DLST levels significantly decreased in microRNA-146a wild-type mice on angiotensin-II administration, whereas DLST protein levels were already higher at baseline in the microRNA-146a knockouts and did not alter on angiotensin-II administration (G, representative Western blot; J, quantification). H and I, Although there was no significant difference between Glut-4 mRNA levels in both strains (H), Glut-1 levels (I) strongly increased in the WT angiotensin-II-treated mice and did not alter in the knockouts. BAS indicates basal; DLST, dihydrolipoyl succinyltransferase; DNP, dinitrophenol; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; (Continued ) ORIGINAL RESEARCH ARTICLE weeks, we observed a 2-fold increase in cardiac DLST protein levels (Figure 3g) . In both the Ang-II and transversal aortic constriction models, a significant decrease in DLST levels occurred in wild-type animals (Figure 3h  and 3i ). In conclusion, we validated DLST as a target of microRNA-146a in vivo.
Cardiomyocytes Lacking MicroRNA-146a Have an Altered Metabolic Profile on Pressure Overload
We isolated adult cardiomyocytes of wild-type and microRNA-146a-/ -mice that were treated for 4 weeks with Ang-II versus control to mimic the in vivo situation. The experimental setup is depicted in Figure 4a . Both fatty acid (Figure 4b ) and glucose oxidation (Figure 4c) tended to decrease in wild-type cells (P=0.05 and P=0.06, respectively) but were preserved in microRNA-146a-/ -cardiomyocytes, indicating that loss of microRNA146a helped to preserve these oxidative fluxes through the TCA cycle after Ang-II treatment. We did not observe significant differences in glycolytic flux between wild-type and microRNA-146a-/ -mice in baseline and on Ang-II treatment (Figure 4d ). When measuring OCR by sequential injection of different mitochondrial compounds (Figure 4e and 4f) in the Ang-treated cells, we observed higher ATP production in microRNA-146a-/ -cardiomyocytes compared with the wild-type cells (as measured on injecting oligomycin), whereas mitochondrial proton leak tended to be lower (Figure 4e and 4f) . The increase of the insulinindependent glucose transporter 1 mRNA, a hallmark of a failing heart-but not of GLUT4-only occurred in wild-type but not microRNA-146a-/ -mice (Figure 4h and 4i). We subsequently performed Western blotting for DLST in whole heart protein lysates and observed that DLST levels decreased after Ang-II treatment of wild-type mice but did not alter in microRNA-146a -/-mice at baseline and after 4 weeks of Ang-II treatment (Figure 4g and 4j) .
Overexpression of DLST in the Heart Protects Against Pressure Overload After Ang-II treatment
To finally confirm the protective role of DLST on pressure overload, an rAAV9-DLST vector was injected intravenously 3 weeks before Ang-II infusion in wild-type mice (Figure 5a ). Overexpression of DLST in whole heart tissue was verified with Western blotting (Figure 5b ). rAAV9-mediated cardiac overexpression of DLST blunted the hypertrophic response on Ang-II treatment as determined by heart weight (Figure 5c ), cardiomyocyte crosssectional area (Figure 5e and 5f), and echocardiographic wall thickness (Figure 5g ), whereas fractional shortening remained unchanged (Figure 5d , Table VIII in the onlineonly Data Supplement). These findings were confirmed in the transversal aortic constriction model ( Figure IIIf through IIIh in the online-only Data Supplement), where fractional shortening was preserved with DLST overexpression (Table IX in the online-only Data Supplement).
As a proof of principle, dichloroacetate, an inhibitor of pyruvate dehydrogenase kinases (negative regulators of pyruvate dehydrogenase that metabolizes pyruvate to acetyl-CoA), and hence stimulator of oxidative flux through the TCA cycle, 20, 21 was administered during pressure overload (Figure 5h and 5i) . Cotreatment of Ang-II treated mice with dichloroacetate for 4 weeks resulted in preserved cardiac function after Ang-II treatment ( Figure 5j , Table X in the online-only Data Supplement). Together these data support our hypothesis that the preservation of oxidative metabolism in the heart can help to prevent progression to LV dysfunction on increased pressure overload, and that upregulated microRNA-146a levels in the cardiomyocyte, because of an interaction with DLST, play a detrimental role in the progression of LV dysfunction (Figure 5k ).
DISCUSSION
In our study, we show that gene inactivation or pharmacological inhibition of microRNA-146a prevents the development of cardiac hypertrophy and LV dysfunction in pressure overload conditions. We identify and validate DLST, a crucial component of the TCA cycle enzyme α-ketoglutarate dehydrogenase complex, as a functional target of microRNA-146a. We also show that overexpression of DLST partially prevents cardiac dysfunction. With respect to currently available literature, this is-to the best of our knowledge-the first time a functional interaction between a microRNA and a TCA cycle enzyme is reported. The upregulation of microRNA-146a-in both human and murine cardiac hypertrophy-and the conservation of the crucial microRNA-146a binding site in the 3'-untranslated region of DLST reflect the importance of this microRNA-146a-DLST interaction. The fact that microRNA-146a upregulation and concomitant DLST inhibition promote heart failure might indicate an unwanted maladaptive response of the heart to pressure overload. Figure 4 Continued. Glut, glucose transporter; KO, knockout; MAX, maximal; NS, not significant; OCR, oxygen consumption rate; and WT, wild type. All data are shown as mean+SEM. *P<0.05 within genotype but between conditions; ***P<0.001 within genotype but between conditions; #P<0.05 between genotypes within same condition; ##P<0.01 between genotypes within same condition; n=3 to 4 per group, 2 or more independent experiments for panels B through E. 
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This study demonstrates that targeting the TCA cycle during pressure overload, through inhibition of the microRNA-146a or overexpressing DLST, helps to protect against cardiac dysfunction. It has been well established that microRNAs are especially important in pathological stress conditions and often less so in normal physiological conditions, 22 helping to explain how global microRNA knockout strains rarely have a phenotype in baseline, unstressed conditions. MicroRNA-146a is produced in endothelial cells, inflammatory cells, and cardiomyocytes. Upregulation of microRNA-146a in cardiac endothelial cells and its subsequent transportation into the cardiomyocytes by exosomes was first described in the development of peripartum cardiomyopathy. 13 Endothelial dysfunction is also a feature of heart failure. 23, 24 Thus, the shedding of microRNA-146a-loaded exosomes from reactive endothelial cells subsequently taken up by the cardiomyocytes may contribute to the progression of heart failure.
The down-regulation of DLST expression per se in pressure overload at first glance is perplexing. It implies less efficient flux through the TCA cycle and impaired energy efficiency, whereas the pressure-overloaded heart has increased energy demands. However, recent studies show that mitochondrial enzymes are key players in energy metabolism and are also capable of generating reactive oxygen species. [25] [26] [27] The latter depends on how well the TCA cycle is replenished (eg, by means of anaplerosis) and on the direction of the TCA cycle, taking into consideration that some of the crucial TCA cycle enzymes are bidirectional. Whether the down-regulation of DLST is an attempt to balance decreased energy efficiency against decreased reactive oxygen species formation remains to be elucidated. [28] [29] [30] Moreover, mitochondrial dysfunction is clearly present in the pressureoverloaded heart because ATP production is impaired, superfluous calcium loading in the mitochondria occurs, and an imbalance between nicotinamide adenine dinucleotide phosphate, reduced form/nicotinamide adenine dinucleotide phosphate, oxidized form and nicotinamide adenine dinucleotide, reduced form/nicotinamide adenine dinucleotide, oxidized form levels instigates an excess production of H 2 O 2 . 31 Recently, first evidence for the role of DLST in cardiovascular disease has been suggested in zebrafish, where a general loss-of-function mutation in the DLST gene caused a lower resting heart rate and an arrhythmia-prone phenotype. 32 Moreover, in a microarray study in murine diabetic cardiomyopathy, microRNA-146a was strongly upregulated, and the in silico pathway analysis suggested that this microRNA was implicated in oxidative stress pathways. 33 The microRNA-146a and its target DLST provide 2 potential therapeutic targets for a novel metabolically oriented treatment for heart failure. The question still remains how this goal can be achieved. The claim that microRNA-146a inhibition or DLST overexpression has therapeutic potential needs to be considered cautiously, with hurdles to overcome if ever anti-miR treatment for heart failure in patients becomes a reality. One of the major issues is the pleiotropic effect of microRNAs, which is part of their nature. 22 In the case of microRNA146a, systemic anti-miR administration might influence inflammatory processes, leading to unwanted side effects. Furthermore, anti-miR therapy currently still fails to be cell-specific and leads to a rather general suppression of microRNA levels. These concerns are equally valid with respect to gene therapy for DLST, with unpredictable side effects and cell-specific targeting still being challenging. 34 Whether pharmacological targeting of DLST would be possible and opportune remains elusive until now. Although the above-mentioned technical hurdles need to be tackled, our observations extend our current knowledge about metabolic alterations during heart failure, opening new areas of research and providing a new therapeutic angle to treat heart failure. Targeting metabolic pathways by microRNAs or other forms of therapy could represent a novel and complementary therapy to current heart failure medications.
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DISCLOSURES
